Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China : A Retrospective Cohort Study
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: China has been using inactivated coronavirus disease 2019 (COVID-19) vaccines as primary series and booster doses to protect the population from severe to fatal COVID-19. We evaluated primary and booster vaccine effectiveness (VE) against Omicron BA.2 infection outcomes.
METHODS: This was a 13-province retrospective cohort study of quarantined close contacts of BA.2-infected individuals. Outcomes were BA.2 infection, COVID-19 pneumonia or worse, and severe/critical COVID-19. Absolute VE was estimated by comparison with an unvaccinated group.
RESULTS: There were 289 427 close contacts ≥3 years old exposed to Omicron BA.2 cases; 31 831 turned nucleic acid amplification test-positive during quarantine, 97.2% with mild or asymptomatic infection, 2.6% with COVID-19 pneumonia, and 0.15% with severe/critical COVID-19. None died. Adjusted VE (aVE) against any infection was 17% for primary series and 22% when boosted. Primary series aVE in adults >18 years was 66% against COVID-19 pneumonia or worse and 91% against severe/critical COVID-19. Booster dose aVE was 74% against pneumonia or worse, and 93% against severe/critical COVID-19.
CONCLUSIONS: Inactivated COVID-19 vaccines provided modest protection from infection, very good protection against pneumonia, and excellent protection against severe/critical COVID-19. Booster doses are necessary to provide strongest protection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:228 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 228(2023), 3 vom: 11. Aug., Seite 261-269 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tang, Lin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 14.08.2023 Date Revised 16.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiad090 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35510217X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35510217X | ||
| 003 | DE-627 | ||
| 005 | 20231226063635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiad090 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM35510217X | ||
| 035 | |a (NLM)37005365 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tang, Lin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China |b A Retrospective Cohort Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.08.2023 | ||
| 500 | |a Date Revised 16.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: China has been using inactivated coronavirus disease 2019 (COVID-19) vaccines as primary series and booster doses to protect the population from severe to fatal COVID-19. We evaluated primary and booster vaccine effectiveness (VE) against Omicron BA.2 infection outcomes | ||
| 520 | |a METHODS: This was a 13-province retrospective cohort study of quarantined close contacts of BA.2-infected individuals. Outcomes were BA.2 infection, COVID-19 pneumonia or worse, and severe/critical COVID-19. Absolute VE was estimated by comparison with an unvaccinated group | ||
| 520 | |a RESULTS: There were 289 427 close contacts ≥3 years old exposed to Omicron BA.2 cases; 31 831 turned nucleic acid amplification test-positive during quarantine, 97.2% with mild or asymptomatic infection, 2.6% with COVID-19 pneumonia, and 0.15% with severe/critical COVID-19. None died. Adjusted VE (aVE) against any infection was 17% for primary series and 22% when boosted. Primary series aVE in adults >18 years was 66% against COVID-19 pneumonia or worse and 91% against severe/critical COVID-19. Booster dose aVE was 74% against pneumonia or worse, and 93% against severe/critical COVID-19 | ||
| 520 | |a CONCLUSIONS: Inactivated COVID-19 vaccines provided modest protection from infection, very good protection against pneumonia, and excellent protection against severe/critical COVID-19. Booster doses are necessary to provide strongest protection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a China | |
| 650 | 4 | |a homologous and heterologous booster | |
| 650 | 4 | |a inactivated COVID-19 vaccines | |
| 650 | 4 | |a vaccine effectiveness | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Wang, Fu-Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Rodewald, Lance E |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xuan-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Si-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Qian-Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiao-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ming-Shuang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Yi-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Li-Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yu-Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Xiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Li-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Ao-Di |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Li-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Xiao-Ya |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Zhao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shu-Guang |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Wei-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Zhi-Yin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Nan-Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Zun-Dong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 228(2023), 3 vom: 11. Aug., Seite 261-269 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:228 |g year:2023 |g number:3 |g day:11 |g month:08 |g pages:261-269 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiad090 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 228 |j 2023 |e 3 |b 11 |c 08 |h 261-269 | ||